Optimal Dose of Vitamin D in COVID-19: Survey of 2338 Indian Doctors brings in a First time consensus - Video

Published On 2022-10-17T11:42:24+05:30 | Updated On 17 Oct 2022 4:21 PM IST

Overview

New Delhi: Vitamin D levels of 40 ng/mL and above confer a better immune-protective response to several infections, including COVID-19, a pan India Survey of 2,338 pan-India Doctors has brought to consensus for the very first time.

For the first time in India, Rastogi et al. issued a consensus statement to explain the therapeutic role of Vitamin D based on the systematic questionnaire-based and Knowledge, Attitudes and Practices (KAP) survey among 2,338 pan-India health care professionals (HCPs).

The observational study has been published in the Asian Journal of Diabetology issue.

Currently, there is a lack of consensus on the use of vitamin D for immune protection and the dose of vitamin D for either prevention or treatment of COVID-19. The goal of the accompanying consensus statement also includes arriving at common dosage and duration of vitamin D for immune modulatory function.

The expert panel highlights the immune-boosting potential of vitamin D and its potential role in decreasing morbidity, mortality, and ICU admission, especially in COVID-19 patients, through regulating cytokine storms via immunomodulatory actions.

The statement offered evidence of vitamin D deficiency in the Indian general population despite the increasing awareness of the role of vitamin D in bone health, cardiovascular metabolism, and immunity. About 30% of HCPs participated in the survey reported that 60-80% of the patients have vitamin D deficiency, while 32% of HCPs in the survey said that 40-60% of the patients have vitamin D deficiency.

With this backed evidence, the consensus statement agreed on a common optimal vitamin D dose at 40 ng/mL and above for maintaining good immunity.

Furtherly, the statement recommends vitamin D supplementation of 60,000 IU/week for 2 to 6 months and 2,000 IU/day for 3 to 6 months in vitamin D-deficient patients for optimal response to therapy in COVID-19 patients.

Reference:

ASHU RASTOGI, JAYA PRAKASH SAHOO et al. Asian Journal of Diabetology, Vol. 23, No. 2, April-June 2022

Speakers

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751